Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-γ-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP)

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 21, Issue 2, 2004, Pages 105-110

  Antoniou, Katerina M ^a   Alexandrakis, Michael G ^a   Sfiridaki, Katerina ^a   Tsiligianni, Ioanna ^a   Perisinakis, Kostas ^a   Tzortzaki, Eleni G ^a   Siafakas, Nikolaos M ^a   Bouros, Demosthenes E ^a,b,c  

^a UNIVERSITY OF CRETE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

BALF; Colchicine; IFN ; IL 12; IL 18; IPF

Indexed keywords

COLCHICINE; CYTOKINE; GAMMA INTERFERON; GAMMA1B INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNOREGULATION; LUNG FIBROSIS; LUNG LAVAGE; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TH1 CELL;

AGED; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; COLCHICINE; CYTOKINES; FEMALE; HUMANS; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-12; INTERLEUKIN-18; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; TH1 CELLS;

EID: 3242692421     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. International Consensus Statement. Idiopathic Pulmonary Fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000; 161: 646-64.
2. Bouros D: Current classification of idiopathic interstitial pneumonias. Monaldi Arch Chest Dis 2000; 55: 450-4.
3. Wallace WA, Ramage EA, Lamb D, Howie SE: A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995; 101: 436-41.
4. Dunkan MR, Berman B: Differential regulation of collagen, glycosaminoglycan, fibronectin, and collagenase activity production in cultured human adult dermal fibroblasts by interleukin-1-alpha and beta tumor necrosis factor-alpha and beta. J Invest Dermatol 1989; 92: 699-706.
5. Giri SN, Hyde DM, Marafino BJ: Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. Biochem Med Metab Biol 1986; 36: 194-7.
6. Keane MP, Strieter RM: The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res 2002; 3: Epub 2001 Oct 15
7. Walker C, Bauer W, Braun RK, et al: Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994; 150: 1038-48.
8. Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
9. Gurujeyalakshmi G, Giri SN: Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: down-regulation of TGF-beta and procollagen 1 and III gene expression. Exp Lung Res 1995; 21: 791-808.
10. Eickelberg O, Pansky A, Koehler E, et al: Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J 2001; 15: 797-806.
11. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH: A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-9.
12. Kalra S, Utz JP, Ryu JH: Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc 2003; 78: 1082-7.
13. Antoniou KM, Polychronopoulos V, Dimadi M, et al: Comparison of Interferon Gamma-1b (IFN-g) and colchicine in the treatment of idiopathic pulmonary fibrosis: Preliminary results of a prospective, multicenter randomized study. Am J Respir Crit Med 2003; 167: A168.
14. Raghu G, Brown KK, Bradford WZ, et al: Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-33.
15. Trinchieri G, Gerosa F: Immunoregulation by interleukin-12. J Leukoc Biol 1996; 59: 505-11.
16. Dinarello CA, Novick D, Puren AJ, et al: Overview of interleukin-18: more than an interferon-γ inducing factor. J Leukoc Biol 1998; 63: 658-64.
17. Coughlin CM, Salhany KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998; 101: 1441-52.
18. Gately MK, Renzetti LM, Magram J, et al: The interleukin-12/interleukin- 12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495-521.
19. D'Andrea A, Rengaraju M, Valiante NM, et al: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-98.
20. Scott P: IL-12: initiation cytokine for cell-mediated immunity. Science 1993; 260: 547-9.
21. Munder M, Mallo M, Eichmann K, Modolell M: Murine macrophages secrete interferon-γ upon combined stimulation with interleukin IL-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med 1998; 187: 2103-8.
22. Keane MP, Belperio JA, Burdick MD, Strieter RM: IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2001; 281: L92-7.
23. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H: Interferon-γ inducing facfor, novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper cells. Cell Immunol 1997; 173: 230-5.
24. Kato Z, Jee J, Shikano H, et al: The structure and binding mode of interleukin-18. Nat Struct Biol 2003; 10: 966-71.
25. Okamura H, Tsutsi H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995; 378: 88-91.
26. Jordan JA, Guo RF, Yun EC, et al: Role of IL-18 in acute lung inflammation. J Immunol 2001; 167: 7060-8.
27. Cameron LA, Taha RA, Tsicopoulos A, et al: Airway epithelium expresses interleukin-18. Eur Respir J 1999; 14: 553-9.
28. Report of the European Society of Pneumology Task Group: Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J 1989; 2: 561-85.
29. Tsiligianni J, Tzanakis N, Kyriakou D, Chrysophakis G, Siafakas NM, Bouros D: Comparison of sputum induction with bronchoalveolar cell differential counts in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 205-10.
30. American Thoracic Society: Standardization of spirometry, update. Am Respir Crit Care Med 1994; 152: 1107-36.
31. Merkus PJ, Verver S, van Essen-Zandvliet EE, Duiverman EJ, Kerrebijn KF, Quanjer PH: Lung volumes measured by the forced rebreathing technique in children with airways obstruction. Eur Respir J 1992; 5: 879-86.
32. Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Hara N: Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1128-1137.
33. Micallef MJ, Ohtsuki T, Kohno K, et al: Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996; 26: 1647-51.
34. Forlani S, Ratta L, Bulgheroni A, et al: Cytokine profile of bronchoalveolar lavage in BOOP and UIP. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 47-53.
35. Selman M, Carrillo G, Salas J, et al: Colchicine, D-penieillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114: 507-512.
36. Lynch JP III, Standiford TJ, Rolfe MW, Kunkel SL, Strieter RM: Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8. Am Rev Respir Dis 1992; 145: 1433-9.
37. Carre PC, Mortenson RL, King TE Jr, Noble PW, Sable CL, Riches DW: Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest 1991; 88: 1802-10.